PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15015196-1	2004	OBJECTIVE: We hypothesize that treatment with Pravastatin, a HMG CoA reductase inhibitor would improve flow-mediated dilation (FMD), a nitric oxide dependent phenomenon and the earliest detectable marker of endothelial dysfunction, in asymptomatic patients with type-1 diabetes.	Nitric Oxide	135-147	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-78	
18504415-1	2008	AIM: The objective of this study was to examine the interaction ofa 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) with a nitric oxide (NO) donor from the perspective of the impact on cardiomyocyte cell viability.	Nitric Oxide	152-164	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	68-125	
12960680-0	2003	The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.	Nitric Oxide	58-70	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-21	
11701613-1	2001	3-Hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors or statins exert direct beneficial effects on the endothelium in part through an increase in nitric oxide (NO) production.	Nitric Oxide	158-170	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-53